AI assistant
Merck & Co., Inc. — Director's Dealing 2024
Feb 2, 2024
284_dirs_2024-02-02_17c64ba0-e332-494d-876f-cf9738d0cc88.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2024-02-02
Reporting Person: MIZELL STEVEN (EVP, Chief HR Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-02 | Common Stock | M | 824 | $70.71 | Acquired | 42143.145 | Direct |
| 2024-02-02 | Common Stock | M | 32170 | $73.73 | Acquired | 74313.145 | Direct |
| 2024-02-02 | Common Stock | S | 50694 | $126.6491 | Disposed | 23619.145 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-02 | Stock Option (Right to Buy) | $70.71 | M | 824 | Disposed | 2028-10-29 | Common Stock (824) | Direct |
| 2024-02-02 | Stock Option (Right to Buy) | $73.73 | M | 32170 | Disposed | 2031-05-03 | Common Stock (32170) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.
F3: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.